biostudies-literatureWarren RBAbbVie50-59https://www.ebi.ac.uk/biostudies/studies/S-EPMC7983954biostudies-literatureUnknown184(1)<h4>Background</h4>Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin-23 and interleukin-17A, respectively, and are effective in adult patients with moderate-to-severe plaque psoriasis but have different dosing regimens.<h4>Objectives</h4>To compare directly the efficacy and safety of risankizumab vs. secukinumab over 52 weeks.<h4>Methods</h4>IMMerge was an international, phase III, multicentre, open-label, efficacy-assessor-blinded, active-comparator study, in which adult patients with chronic, moderate-to-severe plaque psoriasis were randomized in a 1 : 1 ratio to treatment with risankizumab 150 mg or secukinumab 300 mg. Primary efficacy endpointsThe British journal of dermatologyEfficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.PMC7983954GPP3Blauvelt AWarren RBPaul CWu TGeng ZKelly MPoulin YBeeck SfalseEfficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.<h4>Background</h4>Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin-23 and interleukin-17A, respectively, and are effective in adult patients with moderate-to-severe plaque psoriasis but have different dosing regimens.<h4>Objectives</h4>To compare directly the efficacy and safety of risankizumab vs. secukinumab over 52 weeks.<h4>Methods</h4>IMMerge was an international, phase III, multicentre, open-label, efficacy-assessor-blinded, active-comparator study, in which adult patients with chronic, moderate-to-severe plaque psoriasis were randomized in a 1 : 1 ratio to treatment with risankizumab 150 mg or secukinumab 300 mg. Primary efficacy endpoints2021-01-01T00:00:00Z2021 Jan2026-04-07T21:23:01.738Z2025-04-03T21:33:41.175ZS-EPMC79839543259452210.1111/bjd.19341